PXD060523

PXD060523 is an original dataset announced via ProteomeXchange.

Title	Essential role of NLRC5 in cancer immune surveillance and cancer immunoediting
Description	Background/Objectives: Downregulation of NLRC5, the transcriptional activator of MHC class-I, results in tumor immune evasion via escape from CD8+ T cell-mediated tumor control. As NLRC5 deficiency does not abrogate CD8+ T cell development, we investigated whether NLRC5-dependent antitumor immune mechanisms are required for immune surveillance. Methods: Development of 3-methylcholanthrene (MCA)-induced endogenous fibrosarcoma was studied in Nlrc5-/- mice with Nlrc5+/+ and Rag1-/- mice serving as controls. Tumors were histologically examined. Tumor cell lines established from MCA-induced tumors were evaluated for their sensitivity to immune-mediated growth control following implantation into immunocompetent C57BL/6 and immunodeficient Rag1-/- hosts. Proteomes of MCA-induced tumors were analysed by mass spectrometry followed by pathway analysis. Results: Nlrc5-/- and Rag1-/- mice showed increased propensity to develop MCA-induced tumors with elevated growth rate compared to Nlrc5+/+ mice, and displayed significantly reduced survival. Tumors from Nlrc5+/+ and Nlrc5-/- mice, but not from Rag1-/- mice, contained necrotic areas and displayed T cell infiltration. Tumors formed by Nlrc5+/+ tumor cell lines progressed unhindered in C57BL/6 hosts that reflected their immunoedited status, whereas cell lines from Nlrc5-/- and Rag1-/- tumors were efficiently controlled, indicating their non-immunoedited status. Proteomic analysis revealed enrichment of granzyme-mediated cytolytic pathway in Nlrc5+/+ tumors that were absent in Nlrc5-/- tumors, which showed enrichment of humoral and innate immune pathways. Conclusions: Our data show that NLRC5 is required for robust tumor immune surveillance and tumor immunoediting. Compensatory humoral and innate immune mechanisms activated by the loss of NLRC5 are insufficient for cancer immune surveillance and cancer immunoediting.
HostingRepository	PRIDE
AnnounceDate	2025-12-19
AnnouncementXML	Submission_2025-12-19_10:57:14.939.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Jean-Francois Lucier
SpeciesList	scientific name: Mus musculus (Mouse); NCBI TaxID: NEWT:10090;
ModificationList	S-carboxamidomethyl-L-cysteine; monohydroxylated residue
Instrument	Bruker Daltonics instrument model

Revision	Datetime	Status	ChangeLog Entry
0	2025-02-05 09:48:41	ID requested
⏵ 1	2025-12-19 10:57:17	announced

10.1111/sji.70047;

Shukla A, Cayarga AA, Lucier JF, Santharam MA, Quenum AJI, Ihsan AU, L, é, vesque D, Boisvert FM, Ramanathan S, Ilangumaran S, Essential Role of NLRC5 in Cancer Immune Surveillance and Cancer Immunoediting. Scand J Immunol, 102(2):e70047(2025) [pubmed]

submitter keyword: cancer immune surveillance

cancer immunoediting

NLRC5

MHC class-I

3-methylcholanthrene

cytolytic T lymphocyte

granzyme

Subburaj Ilangumaran
contact affiliation	Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada; Centre de Recherche, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada
contact email	subburaj.ilangumaran@usherbrooke.ca
lab head
Jean-Francois Lucier
contact affiliation	Universite de Sherbrooke
contact email	jean-francois.lucier@usherbrooke.ca
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2025/12/PXD060523

PRIDE project URI

• PRIDE
  1. PXD060523
     1. Label: PRIDE project
     2. Name: Essential role of NLRC5 in cancer immune surveillance and cancer immunoediting